Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4924 - Oncotype Dx results in patients _40 years, Does age matters?: new insights

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Fernando Namuche

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

F. Namuche1, R.E. Ruiz2, Z.D. Morante Cruz2, D. Urrunaga3, G. Ziegler4, R. Mantilla4, M. Leon Rivera5, M. Chavez Mac Gregor6, H.L. Gomez Moreno7

Author affiliations

  • 1 Oncology, Oncosalud, LM12 - Lima/PE
  • 2 Oncology, Instituto Nacional de Enfermedades Neoplasicas - INEN, Lima 34 - Lima/PE
  • 3 Medicine, USMP, LM12 - Lima/PE
  • 4 Mastology, URP, LM10 - Lima/PE
  • 5 Oncology, CLINICA RICARDO PALMA, Lima 27 - Lima/PE
  • 6 Health Services Research, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 7 Medicine, Instituto Nacional de Enfermedades Neoplasicas - INEN, Lima 34 - Lima/PE
More

Resources

Abstract 4924

Background

The 21-gene recurrence score (RS) predicts the benefit of adjuvant chemotherapy (CT) in ER-positive, HER2-negative breast cancer (BC) and has been validated in a population where women under 40 are underrepresented. Young BC pts are more likely to receive adjuvant chemotherapy (CT) in addition to endocrine therapy (ET). Our objective was to assess the RS results in young (≤40 yo) vs older (>40 yo) pts and evaluate the impact of age on clinical decision making according to RS categories.

Methods

We retrospectively reviewed electronic medical files of all patients with early stage hormone receptor BC for whom RS was available between 2007 and 2017 in 3 specialized cancer centers. We used the Mann-Whitney and Chi-squared tests to assess differences between age group. Similarly, we evaluated the association between age groups and treatment, within each ODx category. To determine if age was associated with CT use in the low-risk category, a logistic regression model was constructed.

Results

A total of 551 pts were included, 53 (9.6%) ≤40 yo and 498 (90.4%) >40 yo. No statistical differences were found between the younger and older groups in T (p = 0.874), N (p = 0.794), stage (p = 0.188), or grade (p = 0.791). Young patients underwent radical surgery more frequently than their older counterparts (41.5% vs 25.7%, p = 0.014). Statistically significant differences were also observed in ER mean, which was lower in the younger group (80% vs 90%, p < 0.001). The median RS result was significantly higher in the younger group (19 vs 16, p = 0.009). Also, high-risk recurrence score category was significantly more frequent in the younger group (22.6% vs 9.2%, p = 0.009). In the intermediate-risk category there were no differences in the proportion of patients who received CT according to age groups (p = 0.484). In the low-risk category, 28.0% of patients ≤40 years vs 11.3% of patients >40 years received CT (p = 0.037).

Conclusions

Our results indicate that RS tends to be higher in patients with BC ≤ 40 yo and that the frequency of high-risk RS is significantly higher in the younger group, suggesting biological differences between groups. 28% of young patients with low-risk RS from our cohort are overtreated. Based on these results, it should be considered to develop a test adjusted to the age of the patients.

Clinical trial identification

Legal entity responsible for the study

Oncosalud.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings